129 related articles for article (PubMed ID: 28849750)
1. Deciphering structural stability and binding mechanisms of potential antagonists with smoothened protein.
Sinha N; Chowdhury S; Sarkar RR
J Biomol Struct Dyn; 2018 Aug; 36(11):2917-2937. PubMed ID: 28849750
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of drug resistance in smoothened receptor: An in silico study of protein resistivity and specificity.
Sinha N; Chowdhury S; Sarkar RR
Proteins; 2020 Mar; 88(3):514-526. PubMed ID: 31589795
[TBL] [Abstract][Full Text] [Related]
3. Molecular Modelling of Berberine Derivatives as Inhibitors of Human Smoothened Receptor and Hedgehog Signalling Pathway Using a Newly Developed Algorithm on Anti-Cancer Drugs.
Kaboli PJ; Bazrafkan M; Ismail P; Ling KH
Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):384-400. PubMed ID: 28969581
[TBL] [Abstract][Full Text] [Related]
4. Best Matching Protein Conformations and Docking Programs for a Virtual Screening Campaign Against SMO Receptor.
Amendola G; Di Maio D; La Pietra V; Cosconati S
Mol Inform; 2016 Sep; 35(8-9):340-9. PubMed ID: 27546038
[TBL] [Abstract][Full Text] [Related]
5. Ligand-based 3D pharmacophore modeling, virtual screening, and molecular dynamic simulation of potential smoothened inhibitors.
Mohebbi A
J Mol Model; 2023 Apr; 29(5):143. PubMed ID: 37062794
[TBL] [Abstract][Full Text] [Related]
6. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity.
Zhang H; Sun Z; Liu Z; Song C
Future Med Chem; 2018 Dec; 10(24):2855-2875. PubMed ID: 30557039
[TBL] [Abstract][Full Text] [Related]
7. Analysis of vismodegib resistance in D473G and W535L mutants of SMO receptor and design of novel drug derivatives using molecular dynamics simulations.
Liao S; Floyd C; Verratti N; Leung L; Wu C
Life Sci; 2020 Mar; 244():117302. PubMed ID: 31953165
[TBL] [Abstract][Full Text] [Related]
8. Triazoles bind the C-terminal domain of SMO: Illustration by docking and molecular dynamics simulations the binding between SMO and triazoles.
Liu M; Liang G; Zheng H; Zheng N; Ge H; Liu W
Life Sci; 2019 Jan; 217():222-228. PubMed ID: 30543826
[TBL] [Abstract][Full Text] [Related]
9. State of the art of Smo antagonists for cancer therapy: advances in the target receptor and new ligand structures.
Espinosa-Bustos C; Mella J; Soto-Delgado J; Salas CO
Future Med Chem; 2019 Mar; 11(6):617-638. PubMed ID: 30912670
[TBL] [Abstract][Full Text] [Related]
10. Molecular modeling study on the dynamical structural features of human smoothened receptor and binding mechanism of antagonist LY2940680 by metadynamics simulation and free energy calculation.
Bai Q; Shen Y; Jin N; Liu H; Yao X
Biochim Biophys Acta; 2014 Jul; 1840(7):2128-38. PubMed ID: 24637074
[TBL] [Abstract][Full Text] [Related]
11. Colocalization Strategy Unveils an Underside Binding Site in the Transmembrane Domain of Smoothened Receptor.
Zhou F; Ding K; Zhou Y; Liu Y; Liu X; Zhao F; Wu Y; Zhang X; Tan Q; Xu F; Tan W; Xiao Y; Zhao S; Tao H
J Med Chem; 2019 Nov; 62(21):9983-9989. PubMed ID: 31408335
[TBL] [Abstract][Full Text] [Related]
12. Molecular modeling study on resistance of WT/D473H SMO to antagonists LDE-225 and LEQ-506.
Tu J; Li JJ; Song LT; Zhai HL; Wang J; Zhang XY
Pharmacol Res; 2018 Mar; 129():491-499. PubMed ID: 29175550
[TBL] [Abstract][Full Text] [Related]
13. Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays.
Lu W; Zhang D; Ma H; Tian S; Zheng J; Wang Q; Luo L; Zhang X
Eur J Med Chem; 2018 Jul; 155():34-48. PubMed ID: 29857275
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of anthranilamide derivatives as potent SMO inhibitors.
Ji D; Zhang W; Xu Y; Zhang JJ
Bioorg Med Chem; 2020 Mar; 28(6):115354. PubMed ID: 32063403
[TBL] [Abstract][Full Text] [Related]
15. MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.
Hoch L; Faure H; Roudaut H; Schoenfelder A; Mann A; Girard N; Bihannic L; Ayrault O; Petricci E; Taddei M; Rognan D; Ruat M
FASEB J; 2015 May; 29(5):1817-29. PubMed ID: 25636740
[TBL] [Abstract][Full Text] [Related]
16. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
Halder AK; Saha A; Saha KD; Jha T
J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
[TBL] [Abstract][Full Text] [Related]
17. Designing New Kinase Inhibitor Derivatives as Therapeutics Against Common Complex Diseases: Structural Basis of Microtubule Affinity-Regulating Kinase 4 (MARK4) Inhibition.
Naz F; Shahbaaz M; Bisetty K; Islam A; Ahmad F; Hassan MI
OMICS; 2015 Nov; 19(11):700-11. PubMed ID: 26565604
[TBL] [Abstract][Full Text] [Related]
18. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
Arodola OA; Soliman ME
Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
[TBL] [Abstract][Full Text] [Related]
19. Cholesterol Interaction Sites on the Transmembrane Domain of the Hedgehog Signal Transducer and Class F G Protein-Coupled Receptor Smoothened.
Hedger G; Koldsø H; Chavent M; Siebold C; Rohatgi R; Sansom MSP
Structure; 2019 Mar; 27(3):549-559.e2. PubMed ID: 30595453
[TBL] [Abstract][Full Text] [Related]
20. Exploration of New and Potent Lead Molecules Against CAAX Prenyl Protease I of Leishmania donovani Through Pharmacophore Based Virtual Screening Approach.
Prabhu SV; Tiwari K; Suryanarayanan V; Dubey VK; Singh SK
Comb Chem High Throughput Screen; 2017; 20(3):255-271. PubMed ID: 28116998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
